5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer

Abstract

The use of 5-ARIs was not associated with an increased risk of prostate cancer-specific and all-cause mortality in men with a new diagnosis of prostate cancer. While these results provide reassurance, additional studies are needed to replicate these findings.